The well-known pharmaceutical manufacturer AstraZeneca is pulling the Covid-19 vaccine, Vaxzevria, from all international markets. This choice was made after the manufacturer finally admitted that there is a small but potentially dangerous side effect to the vaccine.
More Options, Less Demand for Vaxzevria
According to AstraZeneca, there are no safety concerns behind the withdrawal—rather, it was made for business purposes. There are just too many possibilities accessible because of the emergence of more recent vaccines that target novel variations. The company is no longer producing or delivering Vaxzevria because of a decline in demand.
Vaxzevria’s Role and Safety
Vaxzevria was crucial in the effort to contain the worldwide pandemic. With more than 3 billion doses given globally, estimates indicate it saved more than 6.5 million lives in its first year alone. AstraZeneca highlights its role in bringing the pandemic to a conclusion and expresses pride in Vaxzevria’s accomplishments.
Addressing Rare Side Effects
A extremely uncommon adverse effect known as Thrombosis with Thrombocytopenia Syndrome (TTS), which can result in blood clots and low blood platelet counts, has drawn attention to Vaxzevria in recent months. AstraZeneca argues that the decision to withdraw is solely business and unrelated to the TTS cases, while recognising this possibility in court records.
Keep watching our YouTube Channel ‘DNP INDIA’. Also, please subscribe and follow us on FACEBOOK, INSTAGRAM, and TWITTER.
